Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,795
  • Shares Outstanding, K 82,459
  • Annual Sales, $ 153,730 K
  • Annual Income, $ -106,790 K
  • EBIT $ -130 M
  • EBITDA $ -132 M
  • 60-Month Beta 1.15
  • Price/Sales 0.87
  • Price/Cash Flow N/A
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 293.28% ( +111.74%)
  • Historical Volatility 80.32%
  • IV Percentile 90%
  • IV Rank 38.74%
  • IV High 734.34% on 12/10/24
  • IV Low 14.31% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 60
  • Volume Avg (30-Day) 67
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 3,094
  • Open Int (30-Day) 2,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.86
  • Number of Estimates 9
  • High Estimate -0.68
  • Low Estimate -1.13
  • Prior Year 0.42
  • Growth Rate Est. (year over year) -304.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +14.71%
on 12/19/24
3.0100 -35.22%
on 12/09/24
-0.8900 (-31.34%)
since 12/06/24
3-Month
1.7000 +14.71%
on 12/19/24
4.6000 -57.61%
on 11/11/24
-1.5700 (-44.60%)
since 10/08/24
52-Week
1.7000 +14.71%
on 12/19/24
6.1300 -68.19%
on 03/28/24
-1.5500 (-44.29%)
since 01/08/24

Most Recent Stories

More News
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

STRO : 1.9500 (-3.47%)
Sutro Biopharma and Boehringer Ingelheim BioXcellenceâ„¢ collaboration: Established first-in-class cell-free capabilities at commercial scale

STRO : 1.9500 (-3.47%)
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

STRO : 1.9500 (-3.47%)
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Progress on IND Applications and Clinical Trials

Sutro Biopharma reports significant advancements in ADC technology, ongoing trials, and robust financial resources.Quiver AI SummarySutro Biopharma, Inc. announced in its third-quarter 2024 financial results...

STRO : 1.9500 (-3.47%)
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

STRO : 1.9500 (-3.47%)
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

STRO : 1.9500 (-3.47%)
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

STRO : 1.9500 (-3.47%)
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

STRO : 1.9500 (-3.47%)
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

ONCY : 0.8680 (-5.08%)
NVS : 100.22 (+1.25%)
LNTH : 94.00 (-3.01%)
STRO : 1.9500 (-3.47%)
ZYME : 14.13 (-1.26%)
ONC.TO : 1.30 (+3.17%)
Recent Breakthroughs in Cancer Research Could Impact These Key Companies

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – In the oncology world, there’s...

ONCY : 0.8680 (-5.08%)
ONC.TO : 1.30 (+3.17%)
NVS : 100.22 (+1.25%)
LNTH : 94.00 (-3.01%)
STRO : 1.9500 (-3.47%)
ZYME : 14.13 (-1.26%)

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 2.1100
2nd Resistance Point 2.0700
1st Resistance Point 2.0100
Last Price 1.9500
1st Support Level 1.9100
2nd Support Level 1.8700
3rd Support Level 1.8100

See More

52-Week High 6.1300
Fibonacci 61.8% 4.4377
Fibonacci 50% 3.9150
Fibonacci 38.2% 3.3923
Last Price 1.9500
52-Week Low 1.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar